Compare Quest Diagnostics Inc (DGX) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Micron Technology, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.86 (market cap $25.48B), while Micron Technology, Inc. trades at $1,027.51 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 45.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Micron Technology, Inc. for 48 Days on average.
| DGX | MU | |
|---|---|---|
Market Cap | $25.48B | $1.17T |
Volume | 941,866 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $247.45 | $1.21K |
52-Week Low | $173.49 | $181.60 |
Typical Hold Time | 56 Days | 48 Days |
Enterprise Value | $31.23B | $1.13T |
Dividend Yield | 1.49% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Micron Technology (MU) trades at $1,026.85, down 5.62% over 24 hours, despite strong fundamental performance. The stock shows bullish technical signals with support at $1,020 and resistance at $1,064. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $33.42 surpassing the $31.77 estimate. Revenue surged to $37.38 billion in 2025 with net income of $8.54 billion, while analyst consensus remains strongly bullish with 82.85% buy ratings and a $1,590 price target.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Key risks include cyclical memory pricing and potential growth deceleration. The valuation at P/E 13.94 appears reasonable given robust profitability margins and projected 2026 revenue of $133.2 billion. Institutional sentiment supports further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
